Literature DB >> 19563749

The juxtamembrane region of EGFR takes center stage.

Stevan R Hubbard1.   

Abstract

The activation process for the epidermal growth factor receptor (EGFR) involves formation of an asymmetric dimer of the tyrosine kinase domains. Jura et al. (2009) in this issue and Brewer et al. (2009) in Molecular Cell now demonstrate that the juxtamembrane region of EGFR plays a crucial role in stabilizing this dimer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19563749     DOI： 10.1016/j.cell.2009.06.008

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  14 in total

1.  Bipartite tetracysteine display reveals allosteric control of ligand-specific EGFR activation.

Authors:  Rebecca A Scheck; Melissa A Lowder; Jacob S Appelbaum; Alanna Schepartz
Journal:  ACS Chem Biol       Date:  2012-06-05       Impact factor: 5.100

Review 2.  Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors.

Authors:  Christopher C Valley; Andrew K Lewis; Jonathan N Sachs
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-01-12       Impact factor: 3.747

3.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Authors:  Gianmaria Liccardi; John A Hartley; Daniel Hochhauser
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

4.  MAPK scaffold IQGAP1 binds the EGF receptor and modulates its activation.

Authors:  Dean E McNulty; Zhigang Li; Colin D White; David B Sacks; Roland S Annan
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

Review 5.  EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.

Authors:  Cristina Zahonero; Pilar Sánchez-Gómez
Journal:  Cell Mol Life Sci       Date:  2014-03-27       Impact factor: 9.261

6.  MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

Authors:  Alexa B Turke; Youngchul Song; Carlotta Costa; Rebecca Cook; Carlos L Arteaga; John M Asara; Jeffrey A Engelman
Journal:  Cancer Res       Date:  2012-05-02       Impact factor: 12.701

7.  Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

Authors:  S Tjulandin; V Moiseyenko; V Semiglazov; G Manikhas; M Learoyd; A Saunders; M Stuart; U Keilholz
Journal:  Invest New Drugs       Date:  2013-04-16       Impact factor: 3.850

8.  EGFR: tale of the C-terminal tail.

Authors:  Ketan S Gajiwala
Journal:  Protein Sci       Date:  2013-06-11       Impact factor: 6.725

9.  Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.

Authors:  Takayasu Kurata; Junji Tsurutani; Yasuhito Fujisaka; Wataru Okamoto; Hidetoshi Hayashi; Hisato Kawakami; Eisei Shin; Nobuya Hayashi; Kazuhiko Nakagawa
Journal:  Invest New Drugs       Date:  2014-05-31       Impact factor: 3.850

10.  Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression.

Authors:  Matthew R Hart; Hsin-Yuan Su; Derrick Broka; Aarthi Goverdhan; Joyce A Schroeder
Journal:  Mol Ther       Date:  2013-10-01       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.